IBSA USA
Bill Punia is an accomplished executive in the pharmaceutical industry with extensive experience in supply chain management. Currently serving as Executive Vice President at IBSA USA, Bill Punia leads operations encompassing supply chain, specialty pharmacy, trade, and distribution. Previous roles include Vice President of Supply Chain Operations at BioReference Laboratories, where Bill Punia managed a team of 200 personnel and developed communication strategies. Bill Punia has also held senior positions at Currax Pharmaceuticals and Novartis, focusing on supply planning, external suppliers, negotiation, and strategic sourcing. In addition to a robust career, Bill Punia holds an MBA from the University of Phoenix and a Bachelor of Science in Biology from Montclair State University.
This person is not in any teams
IBSA USA
IBSA USA is the subsidiary of IBSA Group, the largest privately owned pharmaceutical company in Switzerland. IBSA is committed to improving patient quality of life through research, innovation, and the development of effective drugs and cutting-edge technologies. IBSA USA markets two unique levothyroxine formulations in the U.S. for the treatment of hypothyroidism: Tirosint® (levothyroxine sodium) capsules and Tirosint®-SOL (levothyroxine sodium) oral solution. IBSA also markets Licart™ (diclofenac epolamine) topical system 1.3%, the only once-a-day topical nonsteroidal anti-inflammatory (NSAID) available in the U.S. to treat acute pain due to minor strains, sprains, and contusions. IBSA is focused on the health and well-being of patients and driven by the desire to bring therapeutic alternatives to as many people as possible. IBSA Group bases its philosophy on four sustainable pillars: Person, Innovation, Quality, and Responsibility. For more information about Tirosint, Tirosint-SOL, or Licart, including Full Prescribing Information, go to each brand’s respective website.